Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas

NCT05583149 is registered in ClinicalTrials.gov with Patrick C. Johnson, MD as lead sponsor.

NCT NCT05583149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas
Lead sponsor
Patrick C. Johnson, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 1, 2023
Completion date
March 1, 2029
Enrollment
28 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive b-cell nhl, c-myc/bcl2 double-hit high-grade b-cell lymphoma, c-myc/bcl6 double-hit high-grade b-cell lymphoma, de novo or transformed indolent b-cell lymphoma, diffuse large b-cell lymphoma (dlbcl), dlbcl, nos genetic subtypes, ebv-positive dlbcl, nos, grade 3b follicular lymphoma, high-grade b-cell lymphoma, nos, primary mediastinal [thymic] large b-cell lymphoma (pmbcl), refractory aggressive b-cell lymphomas, refractory b-cell non-hodgkin lymphoma, t cell/histiocyte-rich large b-cell lymphoma